Seelos Therapeutics Announces Preclinical Data Showing Treatment With SLS-005 Demonstrated A 46% Reduction In Tau Protein And An 18% Reduction In NfL Biomarker From Baseline Values Within Six Months; Co. To Present Poster At Neuroscience 2023 Nov. 11-15
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics has announced preclinical data showing that treatment with SLS-005 resulted in a 46% reduction in Tau protein and an 18% reduction in NfL biomarker from baseline values within six months. The company will present these findings at Neuroscience 2023 from November 11-15.
September 27, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seelos Therapeutics' preclinical data for SLS-005 shows significant reductions in Tau protein and NfL biomarker, potentially indicating a successful treatment. This could positively impact the company's stock in the short term.
The announcement of positive preclinical data is typically a positive catalyst for biotech companies as it indicates potential success in later stages of clinical trials. This could lead to increased investor confidence in Seelos Therapeutics, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100